China National Pharmaceutical Group Corporation

China National Pharmaceutical Group Corporation (Sinopharm)- are the largest Chinese medical and healthcare group directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC), with the most complete industrial chain coverage and strongest comprehensive competence in China. Our core businesses include distribution, retail, scientific research and manufacture of healthcare related products and we own 11 wholly-owned or holding subsidiaries, and 6 listed companies: Sinopharm Group Co., Ltd., China National Medicines Co., Ltd., Sinopharm Accord Medicines Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd. and China Traditional Chinese Medicine Co. Ltd.. Since Year 2003 to Year 2013, our annual average growth rate of revenue was 31%, annual average growth rate of gross profit was 42% and annual average growth rate of total assets was 32%. In 2013, our sales revenue exceeded RMB 200 billion and became the first Chinese pharmaceutical company who entered Global Top 500. We rank the 357th in Fortune Magazine top 500 2014 and the 8th place among all pharmaceutical enterprises on the list.

With all-out efforts, we are promoting the overall construction of five major platforms – the modern integrated distribution and logistics platform, the integrated manufacturing and R&D platform for scientific and technological innovation, the integrated globally operational platform, the health care industry platform and the highly efficient control and synergy platform and building up the five nationwide networks respectively specialized for pharmaceutical logistics and distribution, retailing pharmacy chain, anaesthetic distribution, cold-chain distribution for biological products and medical equipments and consumable materials distribution, to comprehensively fuel the joint development of the eleven core business sectors of modern pharmaceutical logistics and distribution; medicine retail; biological products; chemical pharmaceuticals; modern traditional Chinese medicines; diagnostics and chemical reagents; scientific instruments and medical equipments; medical scientific research and engineering design; pharmaceutical international trade and overseas industry, pharmaceutical exhibitions and media, and health care industry. So far, we have become an innovation-oriented pharmaceutical and healthcare enterprise.

We own a pharmaceutical and medical distribution network covering 31 provinces, autonomous regions and municipalities and 30 international standard distribution centers, and in the mean time as the largest R & D institution and manufacturer for biological products, we have taken the responsibility of manufacturing more than 80% of EPI vaccines in China. We have built up the production bases for biopharmaceutical products, anaesthetics and psychotropics, anti-infectives, anti-tumors, cardiovascular drugs and respiratory system drugs, and planting bases for medicinal herbs and have the strongest applied medical research institutions and engineering design institute. In 2010, we were elected the national innovation oriented enterprises.

In Chinese pharmaceutical industry, we are the first, the largest and the most successful enterprise to cooperated with foreign companies. We have established dozens of successful Sino-foreign pharmaceutical joint ventures since 1980’s, e.g. China Otsuka Pharmaceutical Co., Ltd. , Sino-Swed Pharmaceutical Co., Ltd. (SSPC), Xian Janssen Pharmaceutical Co., Ltd., Sino-American Squibb Pharmaceutical Co., Ltd. and Suzhou Capsugel Ltd.. We have built up business relations with the clients from over 100 countries and regions, and conducted many international technical collaboration programs. Our pace to go internationalization is being sped up.

Adhering to the corporate credo of 'Caring for life, attending to health', we have always undertaken the responsibility of central reserve, allocation and provision of medicines and health care products against emergencies, disasters and epidemics. Our staff could be found working hard at the emergency sites, e.g. Tangshan Earthquake in 1976, fighting against floods in 1998, prevention and treatment of SARS in 2003, earthquake relief in Wenchuan in 2008, control of influenza A H1N1 in 2009, disaster relief of Yushu Earthquake and Zhouqu Mudslide in 2010, and Lushan Earthquake in 2013. They also appeared at the scene of every significant event for the country, e.g. Beijing Olympic Games in 2008, National Day parade in 2009, Shanghai Expo 2010 and national measles supplementary immunization in 2010. We have been playing a crucial role in securing public health and social stability. With our vaccine products have been exported to India, Thailand, South Korea, Nepal, Sri Lanka, etc., we have also made great contributions to the well being of local public.

As chairman enterprise of several medical industry associations, e.g. China Pharmaceutical Industry Association (CPIA), China National Narcotic Drugs Association (CNNDA), China Association of Pharmaceutical Commerce (CAPC), China Pharmaceutical Industry Research and Development Association (Sino-PhIRDA), China Association for Pharmaceutical Enterprises Promotion (CPEP), Chinese Pharmaceutical Association For & Enterprises Culture Construction (CRAECC), China Society for Pharmaceutical Accountants, and China Association for Pharmaceuticals and Medical Devices Technology Exchange (CPDE), etc. as well as the organizer and sponsor for many pharmaceutical and healthcare exhibitions and conferences, e.g. Phram China, we are playing an important role in nationwide preventing and curing diseases, securing public health and promoting the development of the industry.

We are shooting at the goal of growing into an international pharmaceutical healthcare group, with the whole industrial chain covering business to drive the entire industry forward by 2015.

Editor: Li Jing
Related Stories